Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527

Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine

Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · doi:10.1101/2021.07.28.21261159 · Cited by 1,640

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110345 · Cited by 1,640

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00947-8 · Cited by 1,564

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389

The Development of a Standardized Neighborhood Deprivation Index

Messer, L. C., Laraia, B. A., Kaufman, J. S., Eyster, J. T., Holzman, C., Culhane, J. F., Elo, I. T., Burke, J. G., & O'Campo, P. J. (2006) · Journal of Urban Health · doi:10.1007/s11524-006-9094-x · Cited by 1,046

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.

Sheikh, A., McMenamin, J., Taylor, B., & Robertson, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01358-1 · Cited by 939

Significant Increase in Antibody Titers after the 3rd Booster Dose of the Pfizer–BioNTech mRNA COVID-19 Vaccine in Healthcare Workers in Greece

Κοντοπούλου, Κ., Nakas, C. T., & Papazisis, G. (2022) · Vaccines · doi:10.3390/vaccines10060876 · Cited by 24

Willingness and Perceptions Regarding COVID-19 Vaccine Booster Dose in Pakistani Vaccinated Population: A Cross-Sectional Survey

Moeed, A., Najeeb, H., Saleem, A., Asghar, M. S., Rafi, H. M., Khattak, A. K., Bilal, Z., & Seboka, B. T. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.911518 · Cited by 23

COVID-19 Symptoms by Variant Period in the North Carolina COVID-19 Community Research Partnership, North Carolina, USA

DeWitt, M., Tjaden, A. H., Herrington, D. M., Schieffelin, J. S., Gibbs, M. A., Weintraub, W., Sanders, J. W., & Edelstein, S. L. (2023) · Emerging infectious diseases · doi:10.3201/eid2901.221111 · Cited by 23

Quantifying the effect of delaying the second COVID-19 vaccine dose in England: a mathematical modelling study

Imai, N., Rawson, T., Knock, E., Sonabend, R., Elmaci, Y., Perez‐Guzman, P. N., Whittles, L. K., Kanapram, D. T., Gaythorpe, K. A. M., Hinsley, W. R., et al. (2023) · The Lancet Public Health · doi:10.1016/s2468-2667(22)00337-1 · Cited by 25

Cox regression using a calendar time scale was unbiased in simulations of COVID-19 vaccine effectiveness & safety

Lund, L. C., Støvring, H., Pottegård, A., Andersen, M. T., & Hallas, J. (2023) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2023.02.012 · Cited by 22

Smell and Taste Loss Associated with COVID ‐19 Infection

Mitchell, M. B., Workman, A. D., Rathi, V. K., & Bhattacharyya, N. (2023) · The Laryngoscope · doi:10.1002/lary.30802 · Cited by 25

Vaccine efficacy against SARS-CoV-2 for Pfizer BioNTech, Moderna, and AstraZeneca vaccines: a systematic review

Reynolds, L., Dewey, C. E., Asfour, G., & Little, M. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1229716 · Cited by 24

Estimated Effectiveness of Coadministration of the BNT162b2 BA.4/5 COVID-19 Vaccine With Influenza Vaccine

McGrath, L. J., Malhotra, D., Miles, A. C., Welch, V. L. L., Fusco, M. D., Surinach, A., Barthel, A. B., Alfred, T., Jódar, L., & McLaughlin, J. M. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.42151 · Cited by 23

The role of mild and asymptomatic infections on COVID-19 vaccines performance: A modeling study

Aguiar, M., Van-Dierdonck, J. B., Mar, J., & Stollenwerk, N. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.10.012 · Cited by 23

SARS-CoV-2 variants of concern and vaccine escape, from Alpha to Omicron and beyond

Ong, S. W. X., Chia, T. R. T., & Young, B. E. (2022) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2022.2057299 · Cited by 24

Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS‐CoV‐2 vaccination

Hollstein, M. M., Münsterkötter, L., Schön, M. P., Bergmann, A., Husar, T. M., Abratis, A., Eidizadeh, A., Schaffrinski, M., Zachmann, K., Schmitz, Ä., et al. (2022) · Allergy · doi:10.1111/all.15247 · Cited by 21

Allosteric Binders of ACE2 Are Promising Anti-SARS-CoV-2 Agents

Hochuli, J. E., Jain, S., Melo-Filho, C. C., Sessions, Z. L., Bobrowski, T., Choe, J., Zheng, J., Eastman, R. T., Talley, D. C., Rai, G., et al. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00049 · Cited by 23

Kinetics of vaccine-induced neutralizing antibody titers and estimated protective immunity against wild-type SARS-CoV-2 and the Delta variant: A prospective nationwide cohort study comparing three COVID-19 vaccination protocols in South Korea

Nham, E., Ko, J., Song, K., Choi, J., Kim, E. S., Kim, H., Kim, B., Lim, H.-Y., Kim, K.-C., Jang, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.968105 · Cited by 22

Gam-COVID-Vac, EpiVacCorona, and CoviVac effectiveness against lung injury during Delta and Omicron variant surges in St. Petersburg, Russia: a test-negative case–control study

Барчук, А. А., Bulina, A., Cherkashin, M., Berezina, N., Rakova, T., Kuplevatskaya, D., Skougarevskiy, D., & Okhotin, A. (2022) · Respiratory Research · doi:10.1186/s12931-022-02206-3 · Cited by 24

Coronavirus disease 2019 vaccine effectiveness among a population-based cohort of people living with HIV

Chambers, C., Samji, H., Cooper, C., Costiniuk, C. T., Janjua, N. Z., Kroch, A. E., Arbess, G., Benoit, A. C., Buchan, S. A., Chung, H., et al. (2022) · AIDS · doi:10.1097/qad.0000000000003405 · Cited by 21

Intranasal delivery of a rationally attenuated SARS-CoV-2 is immunogenic and protective in Syrian hamsters

Liu, S., Stauft, C. B., Selvaraj, P., Chandrasekaran, P., D’Agnillo, F., Chou, C., Wu, W. W., Lien, C. Z., Meseda, C. A., Pedro, C. L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34571-4 · Cited by 21

Mucosal immunization with a delta-inulin adjuvanted recombinant spike vaccine elicits lung-resident immune memory and protects mice against SARS-CoV-2

Stewart, E. L., Counoupas, C., Johansen, M. D., Nguyen, D. H., Miemczyk, S., Hansbro, N. G., Ferrell, K. C., Ashhurst, A. S., Alca, S., Ashley, C. L., et al. (2022) · Mucosal Immunology · doi:10.1038/s41385-022-00578-9 · Cited by 23

Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy

Damavandi, A. R., Dowran, R., Sharif, S. A., Kashanchi, F., & Jafari, R. (2022) · Medical Microbiology and Immunology · doi:10.1007/s00430-022-00729-6 · Cited by 21

Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination and Pediatric Age on Delta Variant Household Transmission

Ng, O. T., Koh, V. J. W., Chiew, C. J., Marimuthu, K., Thevasagayam, N. M., Mak, T. M., Chua, J. K., Ong, S. S. H., Lim, Y. K., Ferdous, Z., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac219 · Cited by 21

Bayesian Inference of State-Level COVID-19 Basic Reproduction Numbers across the United States

Mallela, A., Neumann, J., Miller, E. F., Chen, Y., Posner, R. G., Lin, Y. T., & Hlavacek, W. S. (2022) · Viruses · doi:10.3390/v14010157 · Cited by 21

Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study

Shinkai, M., Sonoyama, T., Kamitani, A., Shibata, R. Y., Seki, N. M., Omoto, S., Shinoda, M., Sato, T., Ishii, N., Igarashi, K., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.06.032 · Cited by 19

SARS-CoV-2 Vaccine Breakthrough by Omicron and Delta Variants, New York, USA

Keyel, A. C., Russell, A., Plitnick, J., Rowlands, J. V., Rosenberg, E., Lamson, D. M., McDonough, K. A., & George, K. S. (2022) · Emerging infectious diseases · doi:10.3201/eid2810.221058 · Cited by 23

Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection

Curlin, M. E., Bates, T. A., Guzman, G., Schoen, D., McBride, S. K., Carpenter, S. D., & Tafesse, F. (2022) · Med · doi:10.1016/j.medj.2022.09.001 · Cited by 21

Risk factors for severe Covid-19 breakthrough infections: an observational longitudinal study

Fredj, S. B., Ghammem, R., Zammit, N., Maatouk, A., Haddad, N., Haddad, N., Kachroudi, M., Senda, R., Ladhari, H., Ghodhbani, M. M., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07859-5 · Cited by 27

Dynamic predictors of COVID-19 vaccination uptake and their interconnections over two years in Hong Kong

Yuan, J., Xu, Y., Wong, I. O. L., Lam, W., Ni, M. Y., Cowling, B. J., & Liao, Q. (2024) · Nature Communications · doi:10.1038/s41467-023-44650-9 · Cited by 23

Covid-19 Boosters — Where from Here?

Offit, P. A. (2022) · New England Journal of Medicine · doi:10.1056/nejme2203329 · Cited by 20

Bias and negative values of COVID-19 vaccine effectiveness estimates from a test-negative design without controlling for prior SARS-CoV-2 infection

Wiegand, R. E., FIREMAN, B. H., Najdowski, M., Tenforde, M. W., Link‐Gelles, R., & Ferdinands, J. M. (2024) · Nature Communications · doi:10.1038/s41467-024-54404-w · Cited by 20

Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals

Terpos, E., Karalis, V., Ntanasis‐Stathopoulos, I., Apostolakou, F., Gumeni, S., Gavriatopoulou, M., Papadopoulos, D., Malandrakis, P., Papanagnou, E.-D., Korompoki, E., et al. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000677 · Cited by 20

Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up

Lasagna, A., Lilleri, D., Agustoni, F., Percivalle, E., Borgetto, S., Alessio, N., Comolli, G., Sarasini, A., Bergami, F., Sammartino, J. C., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100359 · Cited by 21

Economic Value of Vaccines to Address the COVID-19 Pandemic in Hong Kong: A Cost-Effectiveness Analysis

Xiong, X., Li, V. J., Huang, B., Tam, T., Hong, Y., Chong, K. C., & Huo, Z. (2022) · Vaccines · doi:10.3390/vaccines10040495 · Cited by 20

Coronavirus Genomes and Unique Mutations in Structural and Non-Structural Proteins in Pakistani SARS-CoV-2 Delta Variants during the Fourth Wave of the Pandemic

Anwar, M. Z., Lodhi, M. S., Khan, M. T., Khan, M. I., & Sharif, S. (2022) · Genes · doi:10.3390/genes13030552 · Cited by 21

Governmental Incentives, Satisfaction with Health Promotional Materials, and COVID-19 Vaccination Uptake among Community-Dwelling Older Adults in Hong Kong: A Random Telephone Survey

Wang, Z. J., Fang, Y., Yu, F.-Y., Chan, P. S.-F., & Chen, S. (2022) · Vaccines · doi:10.3390/vaccines10050732 · Cited by 20

COVID-19 vaccination effectiveness rates by week and sources of bias: a retrospective cohort study

Ostropolets, A., & Hripcsak, G. M. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-061126 · Cited by 18

The first 2 years of COVID-19 in Italy: Incidence, lethality, and health policies

Ferrante, P. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.986743 · Cited by 20

COVID-19 mortality may be reduced among fully vaccinated solid organ transplant recipients

Sandoval, M. N., Nguyen, D. T., Huang, H. J., Yi, S. G., Ghobrial, R. M., Gaber, A. O., & Graviss, E. A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0279222 · Cited by 20

Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination

Nogimori, T., Suzuki, K., Masuta, Y., Yagoto, M., Ikeda, M., Katayama, Y., Washizaki, A., Kanda, H., Takada, M., Minami, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1081047 · Cited by 19

Loss-framing of information and pre-vaccination consultation improve COVID-19 vaccine acceptance: A survey experiment

Wang, K., Wong, E. L., Cheung, A. W.-L., Dong, D., & Yeoh, E. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1063444 · Cited by 23

A modeling-based approach to optimize COVID-19 vaccine dosing schedules for improved protection

Dogra, P., Schiavone, C., Wang, Z., Ruiz-Ramírez, J., Caserta, S., Staquicini, D. I., Markosian, C., Wang, J., Sostman, D. H., Pasqualini, R., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.169860 · Cited by 21

Efficacy and safety of tixagevimab‐cilgavimab versus SARS‐CoV‐2 breakthrough infection in the hematological conditions

Duminuco, A., Nardo, A., Orofino, A., Giunta, G., Conticello, C., Fabro, V. D., Chiarenza, A., Parisi, M. S., Figuera, A., Leotta, S., et al. (2023) · Cancer · doi:10.1002/cncr.35005 · Cited by 20

Changing Patterns of SARS-CoV-2 Seroprevalence among Canadian Blood Donors during the Vaccine Era

Reedman, C. N., Drews, S. J., Yi, Q., Pambrun, C., & O’Brien, S. F. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00339-22 · Cited by 20

Comparative duration of neutralizing responses and protections of COVID-19 vaccination and correlates of protection

Liu, C., Tsang, T. K., Sullivan, S. G., Cowling, B. J., & Yang, B. (2025) · Nature Communications · doi:10.1038/s41467-025-60024-9 · Cited by 19

Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants

Zhang, R., Liu, D., Leung, K., Fan, Y., Lu, L., Chan, P.-C., To, K. K., Chen, H., Yuen, K., Chan, K., et al. (2022) · Vaccines · doi:10.3390/vaccines10010072 · Cited by 20

The allocation of COVID-19 vaccines and antivirals against emerging SARS-CoV-2 variants of concern in East Asia and Pacific region: A modelling study

Leung, K. S. M., Jit, M., Leung, G. M., & Wu, J. T. K. (2022) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100389 · Cited by 21

Effectiveness of BNT162b2 and mRNA-1273 Second Doses and Boosters for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and SARS-CoV-2–Related Hospitalizations: A Statewide Report From the Minnesota Electronic Health Record Consortium

Drawz, P. E., DeSilva, M. B., Bodurtha, P. J., Vazquez‐Benitez, G., Murray, A. M., Chamberlain, A. M., Dudley, R. A., Waring, S. C., Kharbanda, A. B., Murphy, D., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac110 · Cited by 19

Unpacking the Implications of SARS-CoV-2 Breakthrough Infections on COVID-19 Vaccination Programs

Dzinamarira, T., Tungwarara, N., Chitungo, I. J. B., Chimene, M., Iradukunda, P. G., Mashora, M. C., Murewanhema, G., Rwibasira, G. N., & Musuka, G. (2022) · Vaccines · doi:10.3390/vaccines10020252 · Cited by 19

Effectiveness of Ad26.COV2.S Vaccine vs BNT162b2 Vaccine for COVID-19 Hospitalizations

Botton, J., Semenzato, L., Jabagi, M.-J., Baricault, B., Weill, A., Dray‐Spira, R., & Zureik, M. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.0868 · Cited by 19

Retrospective Cohort Study of the Effectiveness of the Sputnik V and EpiVacCorona Vaccines against the SARS-CoV-2 Delta Variant in Moscow (June–July 2021)

Matveeva, O. V., & Ershov, A. (2022) · Vaccines · doi:10.3390/vaccines10070984 · Cited by 19

Exploring Motivations for COVID-19 Vaccination Among Black Young Adults in 3 Southern US States: Cross-sectional Study

Stoner, M. C. D., Browne, E. N., Tweedy, D., Pettifor, A. E., Maragh‐Bass, A. C., Toval, C., Tolley, E. E., Comello, M. L. G., Muessig, K. E., Henna Budhwani, P., et al. (2022) · JMIR Formative Research · doi:10.2196/39144 · Cited by 19

Effectiveness of Pfizer/BioNTech and Sinopharm COVID-19 vaccines in reducing hospital admissions in prince Hamza hospital, Jordan

Al-Momani, H., Al-dajah, K., Alda'ajah, E., ALjafar, Y., & Abushawer, Z. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1008521 · Cited by 20

Randomized clinical trial to assess the impact of oral intervention with cetylpyridinium chloride to reduce salivary SARS‐CoV‐2 viral load

Tarragó‐Gil, R., Gil‐Mosteo, M. J., Aza‐Pascual‐Salcedo, M., Alvarez, M. J. L., Ainaga, R. R., Gimeno, N. L., Viñuales, R. F., Fernández, Y. M., Marco, J. M., Bolsa, E. A., et al. (2022) · Journal Of Clinical Periodontology · doi:10.1111/jcpe.13746 · Cited by 19

Assessment of COVID-19 vaccination among healthcare workers in Iraq; adverse effects and hesitancy

Darweesh, O., Khatab, N., Kheder, R. K., Mohammed, T., Faraj, T. A., Ali, S., Ameen, M., Kamal-Aldin, A., Alswes, M., & Al-Jomah, N. A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274526 · Cited by 19

Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination

Fryer, H. A., Hartley, G. E., Edwards, E. S. J., O’Hehir, R. E., & van Zelm, M. C. (2022) · Biochemical Society Transactions · doi:10.1042/bst20220415 · Cited by 16

Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELD™) and BBV152 (COVAXIN®): a non-inferiority phase 4, participant and observer-blinded, randomised study

Rose, W., Raju, R., Babji, S., George, A., Madhavan, R., Xavier, J. V. L., Chelladurai, J. S. D., Nikitha, O. S., Deborah, A. A., Vijayakumar, S., et al. (2023) · The Lancet Regional Health - Southeast Asia · doi:10.1016/j.lansea.2023.100141 · Cited by 19

Narrative Review of the Evolution of COVID-19 Vaccination Recommendations in Countries in Latin America, Africa and the Middle East, and Asia

Spinardi, J., Dantas, A. C., Carballo, C. M., Thakkar, K. B., Akoury, N. A., Kyaw, M. H., Morales, G. D. C., Srivastava, A. K., & Sáfadi, M. A. P. (2023) · Infectious Diseases and Therapy · doi:10.1007/s40121-023-00804-2 · Cited by 19

COVID-19 vaccine effectiveness against hospitalisation and death of people in clinical risk groups during the Delta variant period: English primary care network cohort study

Whitaker, H., Tsang, R. S. M., Byford, R. C., Aspden, C., Button, E., Pillai, P. S., Jamie, G., Kar, D., Williams, J., Sinnathamby, M., et al. (2023) · Journal of Infection · doi:10.1016/j.jinf.2023.08.005 · Cited by 18

Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome

Valentini, D., Cotugno, N., Scoppola, V., Camillo, C. D., Colagrossi, L., Manno, E. C., Perno, C. F., Russo, C., Palma, P., Rossi, P., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030694 · Cited by 19

A Social Network Analysis of Tweets Related to Mandatory COVID-19 Vaccination in Poland

Olszowski, R., Zabdyr–Jamróz, M., Baran, S., Pięta, P., & Ahmed, W. (2022) · Vaccines · doi:10.3390/vaccines10050750 · Cited by 24

Effectiveness of Covid-19 Vaccines in the United States Over 9 Months: Surveillance Data from the State of North CarolinaPreprint

Lin, D.-Y., Gu, Y., Wheeler, B., Young, H., Holloway, S. T., Sunny, S. K., Moore, Z., & Zeng, D. (2021) · medRxiv · doi:10.1101/2021.10.25.21265304 · Cited by 19

Vaccine effectiveness with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine against reported SARS-CoV-2 Delta and Omicron infection among adolescents, Norway, August 2021 to January 2022Preprint

Veneti, L., Berild, J. D., Watle, S. V., Starrfelt, J., Greve‐Isdahl, M., Langlete, P., Bøås, H., Bragstad, K., Hungnes, O., & Meijerink, H. (2022) · medRxiv · doi:10.1101/2022.03.24.22272854 · Cited by 19

SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic

Shao, Y., Wu, Y., Feng, Y., Xu, W., Xiong, F., & Zhang, X. (2022) · Frontiers of Medicine · doi:10.1007/s11684-021-0913-y · Cited by 20

Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study

Ong, S. W. X., Ren, D., Lee, P. H., Sutjipto, S., Dugan, C., Khoo, B. Y., Tay, J. X., Vasoo, S. S., Young, B. E., & Lye, D. C. (2022) · Antibiotics · doi:10.3390/antibiotics11030345 · Cited by 17

Rates of COVID-19 Among Unvaccinated Adults With Prior COVID-19

Ridgway, J. P., Tideman, S., Wright, B. J., & Robicsek, A. A. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.7650 · Cited by 18

Protection of Messenger RNA Vaccines Against Hospitalized Coronavirus Disease 2019 in Adults Over the First Year Following Authorization in the United States

Tenforde, M. W., Self, W. H., Zhu, Y., Naioti, E. A., Gaglani, M., Ginde, A. A., Jensen, K., Talbot, H. K., Casey, J. D., Mohr, N. M., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac381 · Cited by 21

Vaccine Protection Through Placenta and Breastfeeding: The Unmet Topic in COVID-19 Pandemic

Altoé, A. L., Mambriz, A. P. M., Cardozo, D. M., Zacarias, J. M. V., Visentainer, J. E. L., & Bahls, L. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.910138 · Cited by 19

Change in covid-19 risk over time following vaccination with CoronaVac: test negative case-control study

Hitchings, M. D. T., Ranzani, O., Lind, M. L., Dorión, M., D’Agostini, T. L., de Paula, R. C., de Paula, O. F. P., Villela, E. F. D. M., Torres, M. S. S., de Oliveira, S. B., et al. (2022) · BMJ · doi:10.1136/bmj-2022-070102 · Cited by 18

BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults

Seidel, A., Zanoni, M., Groß, R. M., Krnavek, D., Erdemci-Evin, S., von Maltitz, P., Albers, D., Conzelmann, C., Liu, S., Weil, T., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.882918 · Cited by 17

Durability of Protection Post–Primary COVID-19 Vaccination in the United States

Zheutlin, A. B., Ott, M. Q., Sun, R., Zemlianskaia, N., Meyer, C. S., Rubel, M., Hayden, J., Neri, B., Kamath, T. V., Khan, N. S., et al. (2022) · Vaccines · doi:10.3390/vaccines10091458 · Cited by 19

COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infections, COVID-19 related hospitalizations and deaths, among individuals aged ≥65 years in Portugal: A cohort study based on data-linkage of national registries February-September 2021

Machado, A., Kislaya, I., Rodrigues, A. P., Sequeira, D. J., Lima, J., Cruz, C., Leite, P. P., Dias, C. M., & Nunes, B. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274008 · Cited by 18

Trends in Risk Factors and Symptoms Associated With SARS-CoV-2 and Rhinovirus Test Positivity in King County, Washington, June 2020 to July 2022

Hansen, C., Perofsky, A. C., Burstein, R., Famulare, M., Boyle, S., Prentice, R. A., Marshall, C., McCormick, B., Reinhart, D., Capodanno, B., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.45861 · Cited by 17

Real-World Effectiveness of Four Types of COVID-19 Vaccines

Abdel‐Qader, D. H., Abdel-Qader, H., Silverthorne, J., Kongkaew, C., Meslamani, A. Z. A., Hayajneh, W. A., Alwahadneh, A. M., Hamadi, S., Abu-Qatouseh, L., Awad, R. S., et al. (2023) · Vaccines · doi:10.3390/vaccines11050985 · Cited by 18

Evidence for positive long- and short-term effects of vaccinations against COVID-19 in wearable sensor metrics

Wiedermann, M., Rose, A. H., Maier, B. F., Kolb, J. J., Hinrichs, D., & Brockmann, D. (2023) · PNAS Nexus · doi:10.1093/pnasnexus/pgad223 · Cited by 21

Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice

Slamanig, S., González‐Domínguez, I., Chang, L. A., Lemus, N., Lai, T. Y., Martínez, J. L., Singh, G., Dolange, V., Abdeljawad, A., Kowdle, S., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105185 · Cited by 20

Factors Predicting COVID-19 Vaccine Effectiveness and Longevity of Humoral Immune Responses

Berber, E., & Ross, T. M. (2024) · Vaccines · doi:10.3390/vaccines12111284 · Cited by 22

A Routine Sanger Sequencing Target Specific Mutation Assay for SARS-CoV-2 Variants of Concern and Interest

Lee, S. H. (2021) · Viruses · doi:10.3390/v13122386 · Cited by 18

Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination

Hatzakis, A. E., Karabinis, A., Roussos, S., Pantazis, N., Degiannis, D., Chaidaroglou, A. S., Petsios, K. T., Pavlopoulou, I. D., Tsiodras, S., Paraskevis, D. N., et al. (2022) · Vaccines · doi:10.3390/vaccines10020285 · Cited by 17

AKR1B10, One of the Triggers of Cytokine Storm in SARS-CoV2 Severe Acute Respiratory Syndrome

Chabert, C., Vitte, A.-L., Iuso, D., Chuffart, F., Trocmé, C., Buisson, M., Poignard, P., Lardinois, B., Debois, R., Rousseaux, S., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031911 · Cited by 17

Time trends in social contacts of individuals according to comorbidity and vaccination status, before and during the COVID-19 pandemic

Godbout, A., Drolet, M., Mondor, M., Simard, M., Sauvageau, C., Serres, G. D., & Brisson, M. (2022) · BMC Medicine · doi:10.1186/s12916-022-02398-x · Cited by 17

Breakthrough SARS-CoV-2 infections after COVID-19 immunization

Hirsh, J., Htay, T., Bhalla, S., Nguyen, V. T., & Cervantes, J. (2022) · Journal of Investigative Medicine · doi:10.1136/jim-2021-002131 · Cited by 16

Antibody Responses and Risk Factors Associated With Impaired Immunological Outcomes Following Two Doses of BNT162b2 COVID-19 Vaccination in Patients With Chronic Pulmonary Diseases

Harboe, Z. B., Hamm, S. R., Pérez‐Alós, L., Sivapalan, P., Priemé, H., Wilcke, T., Kjeldgaard, P., Shaker, S. B., Jordan, A. S., Møller, D. L., et al. (2022) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2022-001268 · Cited by 17

Association between Vitamin D Serum Levels and Immune Response to the BNT162b2 Vaccine for SARS-CoV-2

Zelini, P., d’Angelo, P., Cereda, E., Klersy, C., Sabrina, P., Albertini, R., Grugnetti, G., Grugnetti, A. M., Marena, C., Cutti, S., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10081993 · Cited by 18

Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey

Kobashi, Y., Kawamura, T., Shimazu, Y., Zhao, T., Sugiyama, A., Nakayama, A., Kaneko, Y., Nishikawa, Y., Omata, F., Takita, M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-21797-x · Cited by 16

Incidence of Lyme Borreliosis in Germany: A retrospective observational healthcare claims study

Brestrich, G., Hagemann, C., Diesing, J., Kossack, N., Stark, J. H., Pilz, A., Angulo, F. J., Yu, H., & Suess, J. (2024) · Ticks and Tick-borne Diseases · doi:10.1016/j.ttbdis.2024.102326 · Cited by 17

Persistence of protection against SARS-CoV-2 clinical outcomes up to 9 months since vaccine completion: a retrospective observational analysis in Lombardy, Italy

Corrao, G., Franchi, M., Cereda, D., Bortolan, F., Zoli, A., Leoni, O., Borriello, C. R., Valle, G. P. D., Tirani, M., Pavesi, G., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00813-6 · Cited by 21

Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis

Bestvina, C. M., Whisenant, J. G., Torri, V., Cortellini, A., Wakelee, H. A., Peters, S., Roca, E., Toma, A. D., Hirsch, F. R., Mamdani, H. M., et al. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100335 · Cited by 17

An intranasally administrated SARS-CoV-2 beta variant subunit booster vaccine prevents beta variant replication in rhesus macaques

Sui, Y., Li, J., Andersen, H., Zhang, R., Prabhu, S. K., Hoang, T. N., Venzon, D. J., Cook, A., Brown, R., Teow, E., et al. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac091 · Cited by 15

Anti-TNFα Treatment Impairs Long-Term Immune Responses to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases

Rabinowitz, K. M., Navon, M., Edelman-Klapper, H., Zittan, E., Shitrit, A. B., Goren, I., Avni‐Biron, I., Ollech, J. E., Lichtenstein, L., Banai-Eran, H., et al. (2022) · Vaccines · doi:10.3390/vaccines10081186 · Cited by 18

A Bayesian network analysis quantifying risks versus benefits of the Pfizer COVID-19 vaccine in Australia

Sinclair, J. E., Mayfield, H. J., Short, K. R., Brown, S. J., Puranik, R., Mengersen, K. L., Litt, J. C. B., & Lau, C. L. (2022) · npj Vaccines · doi:10.1038/s41541-022-00517-6 · Cited by 18

Lipid nanoparticles deliver DNA-encoded biologics and induce potent protective immunity

Chai, D., Wang, J., Lim, J. M., Xie, X., Yu, X., Zhao, D., Maza, P. A. M., Wang, Y., Cyril-Ramirez, D. R., Young, K. H., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02211-8 · Cited by 21

Serum Antibody Response Comparison and Adverse Reaction Analysis in Healthcare Workers Vaccinated with the BNT162b2 or ChAdOx1 COVID-19 Vaccine

Lim, S. H., Choi, S.-H., Kim, B., Kim, J., Ji, Y.-S., Kim, S., Kim, C. K., Kim, T., Choo, E. J., Moon, J. E., et al. (2021) · Vaccines · doi:10.3390/vaccines9121379 · Cited by 16

Evasion of Vaccine-Induced Humoral Immunity by Emerging Sub-Variants of SARS-CoV-2

Koyama, T., Miyakawa, K., Tokumasu, R., Jeremiah, S. S., Kudo, M., & Ryo, A. (2022) · Future Microbiology · doi:10.2217/fmb-2022-0025 · Cited by 15

Effectiveness of mRNA-1273, BNT162b2, and JNJ-78436735 COVID-19 Vaccines Among US Military Personnel Before and During the Predominance of the Delta Variant

Eick-Cost, A. A., Ying, S., & Wells, N. Y. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.8071 · Cited by 17

Masks, money, and mandates: A national survey on efforts to increase COVID-19 vaccination intentions in the United States

Sargent, R. H., Laurie, S., Moncada, L., Weakland, L. F., Lavery, J. V., Salmon, D. A., Orenstein, W. A., & Breiman, R. F. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267154 · Cited by 16

Will People Accept a Third Booster Dose of the COVID-19 Vaccine? A Cross-Sectional Study in China

Sun, Y., Dai, H., Wang, P., Zhang, X., Cui, D., Huang, Y., Zhang, J., & Xiang, T. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.914950 · Cited by 17

Durability analysis of the highly effective BNT162b2 vaccine against COVID-19

Puranik, A., Lenehan, P. J., O’Horo, J. C., Pawlowski, C., Niesen, M. J. M., Virk, A., Swift, M. D., Kremers, W. K., Venkatakrishnan, A., Gordon, J. E., et al. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac082 · Cited by 16

Protecting the Offspring, the Gift of Maternal Immunization: Current Status and Future Perspectives

Lagousi, T., Gkentzi, D., Geropeppa, M., Tsagkli, P., & Spoulou, V. I. (2022) · Vaccines · doi:10.3390/vaccines10111953 · Cited by 17

The role of machine learning in health policies during the COVID-19 pandemic and in long COVID management

Varón, L. S., González-Puelma, J., Medina-Ortiz, D., Aldridge, J., Álvarez-Saravia, D., Uribe-Paredes, R., & Navarrete, M. A. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1140353 · Cited by 19

mRNA vaccination boosts S-specific T cell memory and promotes expansion of CD45RAint TEMRA-like CD8+ T cells in COVID-19 recovered individuals

Mayer-Blackwell, K., Ryu, H., Codd, A. S., Parks, K. R., MacMillan, H. R., Cohen, K. W., Stewart, T. L., Seese, A. M., Lemos, M. P., Rosa, S. C. D., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101149 · Cited by 16

Effectiveness of the booster dose of inactivated COVID-19 vaccine against Omicron BA.5 infection: a matched cohort study of adult close contacts

Zeng, T., Lu, Y., Zhao, Y., Guo, Z., Sun, S., Teng, Z., Tian, M., Wang, J., Li, S., Fan, X., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02542-y · Cited by 17

COVID-19 Vaccine Effectiveness: A Review of the First 6 Months of COVID-19 Vaccine Availability (1 January–30 June 2021)

Hatcher, S. M., Endres‐Dighe, S. M., Angulo, F. J., Srivastava, A. K., Nguyen, J. L., Khan, F. L., Martin, C., Swerdlow, D. L., McLaughlin, J. M., Ubaka-Blackmoore, N., et al. (2022) · Vaccines · doi:10.3390/vaccines10030393 · Cited by 17

A Shot in the Arm for Vaccination Intention: The Media and the Health Belief Model in Three Chinese Societies

Liu, R., Huang, Y. C., Sun, J., Lau, J., & Cai, Q. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19063705 · Cited by 16

Six-Month Effectiveness of BNT162B2 mRNA COVID-19 Vaccine in a Large US Integrated Health System: A Retrospective Cohort StudyPreprint

Tartof, S. Y., Slezak, J. M., Fischer, H. J., Hong, V. X., Ackerson, B. K., Ranasinghe, O. N., Frankland, T. B., Ogun, O. A., Zamparo, J. M., Gray, S., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3909743 · Cited by 30

Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant

Risk, M., Shen, C., Hayek, S. S., Holevinski, L., Schiopu, E., Freed, G. L., Akin, C., & Zhao, L. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac106 · Cited by 28

BNT162b2 (Pfizer–Biontech) mRNA COVID-19 Vaccine Against Omicron-Related Hospital and Emergency Department Admission in a Large US Health System: A Test-Negative Design

Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V. X., Xie, F., Ackerson, B. K., Valluri, S. R., Jódar, L., & McLaughlin, J. M. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00101-1 · Cited by 151

BNT162b2 Effectiveness and Durability Against BA.1 and BA.2 Hospital and Emergency Department Admissions in a Large US Health System: A Test-Negative DesignPreprint

Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V. X., Xie, F., Ackerson, B. K., Valluri, S. R., Jódar, L., & McLaughlin, J. M. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4150500 · Cited by 2

Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study

Fabiani, M., Puopolo, M., Morciano, C., Spuri, M., Alegiani, S. S., Filia, A., D’Ancona, F. “., Manso, M. D., Riccardo, F., Tallon, M., et al. (2022) · BMJ · doi:10.1136/bmj-2021-069052 · Cited by 111